The year 2020 began with the industry planning to further rise in the medtech, biopharma and startups space within the Asia Pacific (APAC) region. The overall focus in 2020 was intended to be on applied research and adaptation of new technologies, with emphasis on affordability and manageability for APAC companies. But the ongoing COVID-19 pandemic casted a spell of uncertainty across the world putting the capabilities of the life sciences industry on test.
The SARS-CoV-2 virus, which emerged as an unknown pneumonia-like disease in December 2019, gained the status of a global health crisis, by March 2020. Enforced lockdowns caused temporary shutdown of labs and production facilities. The effect of COVID-19 was so enormous that thousands of clinical trials, around 80 per cent of non-COVID-19 trials, were stopped or interrupted.
Many researchers were pulled away from working on clinical trials to work in emergency medical care, especially during the initial months of the pandemic in places where the pandemic threatened to overwhelm critical care resources. In terms of indication, oncology saw the highest number of disrupted clinical trials followed by central nervous system, infectious diseases, gastrointestinal and respiratory diseases.
This story is from the December 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
New South Wales government injects $5M for critical research to address Silicosis crisis
The New South Wales (NSW) government in Australia has committed $5 million in critical funding for silicosis research and a patient support programme for individuals and their families navigating the health risks associated with exposure to silica dust.
Singapore approves new asthma indication for GSK's Trelegy Ellipta
GSK Singapore has announced that the Health Sciences Authority (HSA) has approved a new indication and a new strength for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a combination of a long-acting beta2-agonist (LABA) and an inhaled corticosteroid (ICS).
From Haematologic to Autoimmune DiseaseThe CAR-T Therapy Second Revolution
Cell and gene therapies have revolutionised the field of medicine, offering new treatment options for patients with various diseases that, by type of disease or severity, were considered untreatable until a few years ago. Rapid technological advancements in genetic and biological engineering and improvements in the quality and standardisation of the manufacturing process are fostering a marked increase in clinical development of these advanced therapies, generally named cell and gene therapies CGT), and they are expected to receive more approvals in the near future.
"Biotech startups still need support in terms of talent, and resources to bring their innovations to market"
Raymond Chow has recently stepped in as the Vice President, Asia Pacific at USheadquartered Cytiva, a global provider of technologies and services for biological therapies, formerly known as GE Healthcare Life Sciences.
"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"
US-based Uvax Bio, LLC, a spin-off vaccine company from Scripps Research, employs proprietary 1c-SApNP platform technology invented by Dr Jiang Zhu of Scripps Research to develop and commercialise prophylactic vaccines for challenging infectious diseases.
What Are the Main Challenges of Modern Clinical Trials?
With a cumulative total of almost 478,000 globally registered trials from the year 2000 to 2023, and growing at around 10 per cent a year in the last five years, the pharmaceutical industry continues to invest in clinical trials as the gold-standard test of therapeutic safety and efficacy. In addition, as the world’s economies and populations move in new directions, the share of non-US trials has reached 54 per cent, a trend that is likely to continue, driven by demographics and epidemiology. As the pace accelerates, trial managers and clinicians face a significant challenge: the explosive growth of data volumes. To succeed in the future, clinical trials need to increase efficiency and better utilise clinical trial data to support informed clinical and operational decision-making.
How APAC Has Turned into Clinical Trial Behemoth
From being a consistent participant in clinical trial conduct worldwide, the APAC has emerged as a major power. A number of causes, including the region's thriving drug development innovation and the ongoing presence of international pharmaceutical corporations conducting multiregional studies, are driving this growth.
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
